SPARK NS Awards Five Projects Up to $10 Million to Advance Academic Discoveries in Parkinson’s Disease from the Lab to the Clinic
August 20, 2024 09:46 ET
|
SPARK NS
MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SPARK NS today announced the five projects and principal investigators selected for the 2024 SPARK NS Parkinson’s Disease Translational Research...
Cell and Gene Therapy in Parkinson's Disease Market to Register Stunning Growth During the Study Period (2020–2034) | DelveInsight
July 22, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 22, 2024 (GLOBE NEWSWIRE) -- Cell and Gene Therapy in Parkinson's Disease Market to Register Stunning Growth During the Study Period (2020–2034) | DelveInsight The cell and...
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
July 16, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
June 25, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic...
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
June 25, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Afamelanotide in fair-skinned Parkinson’s patients
June 17, 2024 20:39 ET
|
Clinuvel Pharmaceuticals Limited
CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
May 28, 2024 07:00 ET
|
NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
April 30, 2024 08:00 ET
|
Alumis Inc
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 17, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
Parkinson’s Disease Increasing In U.S., Highlighting Importance Of SSDI Benefits, Allsup Explains
April 16, 2024 12:32 ET
|
Allsup
Belleville, Illinois, April 16, 2024 (GLOBE NEWSWIRE) -- The number of Americans with Parkinson’s disease (PD) continues to increase, highlighting the importance of financial supports for...